A5085943321- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Ubiquitin and proteasome pathways
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis
- CAR-T cell therapy research
- Parkinson's Disease Mechanisms and Treatments
- NF-κB Signaling Pathways
- Immune Cell Function and Interaction
- Acute Myeloid Leukemia Research
- MicroRNA in disease regulation
- RNA modifications and cancer
- Advanced Drug Delivery Systems
- T-cell and Retrovirus Studies
- Botulinum Toxin and Related Neurological Disorders
- Bacteriophages and microbial interactions
- T-cell and B-cell Immunology
- Monoclonal and Polyclonal Antibodies Research
- Galectins and Cancer Biology
- Traditional Chinese Medicine Analysis
- Ginseng Biological Effects and Applications
- Nerve injury and regeneration
- Histone Deacetylase Inhibitors Research
Jilin University
2015-2025
Wuhan University
2022-2025
Renmin Hospital of Wuhan University
2022-2025
Bristol-Myers Squibb (United States)
2020-2025
Xiamen University
2025
Yantai University
2013-2025
Baylor College of Medicine
2019-2025
Shenzhen Institutes of Advanced Technology
2025
The First People's Hospital of Guiyang
2025
National Institutes of Health
2014-2024
Diffuse large B-cell lymphomas (DLBCLs) are phenotypically and genetically heterogeneous. Gene-expression profiling has identified subgroups of DLBCL (activated B-cell–like [ABC], germinal-center [GCB], unclassified) according to cell origin that associated with a differential response chemotherapy targeted agents. We sought extend these findings by identifying genetic subtypes based on shared genomic abnormalities uncover therapeutic vulnerabilities tumor genetics.
The most common human leukemia is B cell chronic lymphocytic (CLL), a malignancy of mature cells with characteristic clinical presentation but variable course. rearranged immunoglobulin (Ig) genes CLL may be either germ-line in sequence or somatically mutated. Lack Ig mutations defined distinctly worse prognostic group patients raising the possibility that comprises two distinct diseases. Using genomic-scale gene expression profiling, we show characterized by "signature," irrespective...
Using current diagnostic criteria, primary mediastinal B cell lymphoma (PMBL) cannot be distinguished from other types of diffuse large (DLBCL) reliably. We used gene expression profiling to develop a more precise molecular diagnosis PMBL. PMBL patients were considerably younger than DLBCL patients, and their lymphomas frequently involved thoracic structures but not extrathoracic sites typical DLBCLs. had relatively favorable clinical outcome, with 5-yr survival rate 64% compared 46% for...
The gene encoding the BCL-6 transcriptional repressor is frequently translocated and mutated in diffuse large cell lymphoma. Mice with a disrupted developed myocarditis pulmonary vasculitis, had no germinal centers, increased expression of T helper type 2 cytokines. DNA recognition motif resembled sites bound by STAT (signal transducers activators transcription) transcription factors, which mediate cytokine signaling. could repress interleukin-4 (IL-4)-induced when to site recognized...
Abstract We have identified two intronic regions of mouse prdm1, the gene encoding B lymphocyte-induced maturation protein-1 (Blimp-1), which confer transcriptional repression in response to Bcl-6. The Bcl-6 element intron 5, is conserved between mice and humans, was studied detail. It binds vitro shown by chromatin immunoprecipitation be occupied vivo. Neither functions as a STAT3-response element, showing that STAT3 does not compete with at these sites. Bcl-6−/− confirm biological...
Current efforts in the proteolysis targeting chimera (PROTAC) field mostly focus on choosing an appropriate E3 ligase for target protein, improving binding affinities towards protein and ligase, optimizing PROTAC linker. However, due to large molecular weights of PROTACs, their cellular uptake remains issue. Through comparing how different warhead chemistry, reversible noncovalent (RNC), covalent (RC), irreversible (IRC) binders, affects degradation Bruton's Tyrosine Kinase (BTK), we...
This open-label, randomized, phase 3 trial (NCT02577406) compared enasidenib, an oral IDH2 (isocitrate dehydrogenase 2) inhibitor, with conventional care regimens (CCRs) in patients aged ≥60 years late-stage, mutant-IDH2 acute myeloid leukemia (AML) relapsed/refractory (R/R) to 2 or prior AML-directed therapies. Patients were first preselected a CCR (azacitidine, intermediate-dose cytarabine, low-dose supportive care) and then randomized (1:1) enasidenib 100 mg per day CCR. The primary...
ABSTRACT Introduction In the OPTIMISMM trial, pomalidomide/bortezomib/dexamethasone (PVd) significantly prolonged median progression‐free survival (PFS) versus bortezomib/dexamethasone (Vd) in lenalidomide‐exposed relapsed and refractory multiple myeloma (RRMM). We report final overall (OS) updated efficacy analyses. Methods Adults with RRMM who had 1–3 prior regimens, including lenalidomide (≥ 2 cycles), were assigned (1:1) to PVd or Vd. Primary endpoint: PFS. Prespecified secondary OS....
Abstract This study suggests a modified model of TNFR1-induced complex I-mediated NFκB signaling. Evaluation panel five tumor cell lines (HCT116-PIK3CAmut, SK-MEL-23, HeLa-RIPK3, HT29, D10) with TRAF2 knockout revealed in two (HT29, HeLa-RIPK3) sensitizing effect for death receptor-induced necroptosis and one line (D10) mild sensitization apoptosis. deficiency inhibited classical NFκB-mediated production IL-8 only subset partly. TRAF5, furthermore, failed to improve DR-induced signaling...
The <i>BRCA1</i> tumor suppressor encodes a polypeptide with two recognizable protein motifs: RING domain near the N terminus and tandem BRCT domains at C terminus. Studies of tumor-associated mutations indicate that sequences are required for BRCA1-mediated suppression. In addition, recent work has shown BRCA1 is potent regulator RNA transcription also essential this activity. Therefore, we used Sos recruitment system to screen proteins bind critical region BRCA1. Our results show interact...
Adult T cell leukemia/lymphoma (ATLL) is an aggressive malignancy caused by human lymphotropic virus type-I (HTLV-I) without curative treatment at present. To illuminate the pathogenesis of ATLL we performed whole transcriptome sequencing purified patient samples and discovered recurrent somatic mutations in CCR4, encoding CC chemokine receptor 4. CCR4 were detected 14/53 (26%) consisted exclusively nonsense or frameshift that truncated coding region C329, Q330, Y331 carboxy terminus....
Efficient delivery of brain-targeted drugs is highly important for successful therapy in Parkinson's disease (PD). This study was designed to formulate borneol and lactoferrin co-modified nanoparticles (Lf-BNPs) encapsulated dopamine as a novel drug system achieve maximum therapeutic efficacy reduce side effects PD. Dopamine Lf-BNPs were prepared using the double emulsion solvent evaporation method evaluated physicochemical pharmaceutical properties. In vitro cytotoxicity studies indicated...